UnknownNot Applicable

Myocardial Fibrosis Identification in Patients With Anthracycline-induced Cardiotoxicity

Italy100 participantsStarted 2018-02-22

Plain-language summary

This is an interventional study for patients who had developed Anthracycline-Induced Cardiotoxicity (AIC) during or after anthracycline-containing therapy, referred to the Cardioncology Unit for heart failure treatment

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients who developed AIC during or after anthracycline-containing therapy assessed by LVEF valuation by echocardiography. Exclusion Criteria: * Age \<18 years * Contraindications to contrast medium magnetic resonance imaging

What they're measuring

Evaluation of blood levels of Suppression Of Tumorigenicity 2 (ST2)

Timeframe: 1 month

Evaluation of blood levels of Galectin-3 (Gal-3)

Timeframe: 1 month

Evaluation of Enhanced Liver Fibrosis score (ELF)

Timeframe: 1 month

Evaluation of CMR imaging marker of fibrosis

Timeframe: 1 month

Trial details

NCT IDNCT06331806

SponsorEuropean Institute of Oncology

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

Contact for this trial

Daniela Cardinale, MD

+39 0257489748 daniela.cardinale@ieo.it

View on ClinicalTrials.gov More Cardiomyopathy Due to Drug trials